A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Metastatic Biliary Tract Cancer Clinical Trial

Official title:

Camrelizumab Combined With Apatinib and Gemcitabine Plus Cisplatin as First-line Therapy for Patients With Inoperable/Metastatic Biliary Tract Cancer (BTC): An Open-label, Single-arm, Single-center, Phase Ib/II Clinical Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05742750
• Other study ID #: 22-OBU-GD-EC-II-005
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: March 1, 2023
• Est. completion date: December 30, 2024

Study information

• Verified date: February 2023
• Source: Sun Yat-sen University
• Contact: Dongsheng Zhang, M.D., Ph.D.
• Phone: 86-02087343795
• Email: zhangdsh[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to investigate the safety and tolerability of camrelizumab combined with apatinib and chemotherapies (gemcitabine and cisplatin) in patients with advanced biliary tract cancer (BTC).

Description:

The study consists of 2 parts, a dose-escalation part (Phase 1) and an expansion part (Phase 2). Both parts will enroll participants with advanced unresectable biliary tract cancer that had not previously treated with systemic therapy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 48
• Est. completion date: December 30, 2024
• Est. primary completion date: December 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subject must be able to comprehend and willing to sign an informed consent form (ICF).

2. Subject must have a pathologically or cytologically confirmed carcinoma (except neuroendocrine) of the biliary tract (intra-hepatic, extra-hepatic (hilar, distal) or gallbladder) that is not eligible for curative resection, transplantation, or ablative therapies. Tumors of mixed cholangiocarcinoma/hepatocellular carcinoma histology are excluded.

3. Subject must be 18-75 years of age at the time of signature of the ICF.

4. Subject must have an ECOG performance status of 0-1. Estimated life expectancy no less than 3 months.

5. Subject may not have received prior systemic treatment (chemotherapy or targeted therapy) for advanced BTC. Prior peri-operative chemotherapy is permitted provided it was completed > 6 months from enrollment.

6. Subject must have a lesion that can be accurately assessed at baseline by CT or magnetic resonance imaging (MRI) and is suitable for repeated assessment in accordance with RECIST v1.1.

7. Subject must have normal organ and marrow function as defined below within 14 days of

study entry:

1. Absolute neutrophil count (ANC) = 1.5 × 10^9/L, platelets = 75 × 10^9/L, or hemoglobin = 9 g/dL.

2. International normalized ratio (INR) < 1.5 or a prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits. Patients receiving anticoagulation treatment with an agent such as warfarin will not be candidates for the trial. Patients on anticoagulation with low molecular weight or heparinoids are protocol candidates.

3. Total bilirubin = 1.5 × upper limit of normal (ULN) unless liver metastasis or BTC in which case = 5 × ULN is permitted at the investigator's discretion. Aspartate transaminase (AST) and Alanine transaminase (ALT) = 3 × ULN.

4. Creatinine = 1.5 × ULN, or creatinine clearance = 50 mL/min (measured or calculated by Cockcroft and Gault equation).

5. Baseline left ventricular ejection fraction (LVEF) = 60% measured by echocardiography or Multiple Gated Acquisition Scan (MUGA)

Exclusion Criteria:

• Patients with any of the following were excluded from the study:

1. Any investigational agents or study drugs from a previous clinical study within 4 weeks of the first dose of study treatment.

2. Malignancies other than BTC within 5 years prior to study enrollment, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent, or breast ductal carcinoma in situ treated surgically with curative intent).

3. Prior history of brain metastasis (unless previously treated, asymptomatic and stable for at least 3 months) or organ transplant.

4. Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.

5. Active bleeding during the last 4 weeks prior to screening or in the investigator's judgment, the existence of high bleeding tendency lesions such as active gastrointestinal ulcers or prominent esophageal or gastric varices.

6. Significant cardiovascular disease, including:

1. Heart disease classified as New York Heart Association class III or IV.

2. Ongoing uncontrolled hypertension.

3. History of congenital long QT syndrome.

4. Ongoing prolonged QT interval corrected for heart rate using Fridericia's method (QTcF) defined as = 470 msec.

7. History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation).

8. Subjects with atrial fibrillation, that is well controlled with treatment, can be enrolled. Active heart disease including symptomatic heart failure (NYHA class 3 or 4), unstable angina pectoris, uncontrolled cardiac arrhythmia or interstitial lung disease. Prolonged QTcF interval >480 msec.

9. Ongoing active, uncontrolled infection (must be afebrile for > 48 hours off antibiotics).

10. With the exception of alopecia, any unresolved toxicities from prior therapy =Common Terminology Criteria for Adverse Events (CTCAE) Grade 2.

11. Pregnancy or breastfeeding. (Women must not be pregnant or breastfeeding since study drugs may harm the fetus or child. All females of childbearing potential [not surgically sterilized and between menarche and 1 year post menopause] must have a negative screening pregnancy test.)

12. History of human immunodeficiency virus infection.

13. History of autoimmune disease.

14. Ascertained hypersensitivity to gemcitabine, cisplatin, camrelizumab or apatinib, or drugs with similar chemical structures, or its inactive components. If there is suspicion that the subject may have an allergy, the subject should be excluded.

15. Psychiatric illness, other significant medical illness, or social situation which, in the investigator's opinion, would limit compliance or ability to comply with study requirements. Judgment by the investigators that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

Related Conditions & MeSH terms

• Biliary Tract Neoplasms
• Locally Advanced Biliary Tract Cancer
• Metastatic Biliary Tract Cancer

Intervention

Drug:
• Camrelizumab and Apatinib Plus GP
Patients received apatinib orally at 250 mg once a day irrespective of the patient weight. Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks. GP chemotherapy: Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle and up to 8 cycles. All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.

Locations

Country	Name	City	State
China	Cancer center of SunYat-sen University	Guangzhou	Guangdong

Sponsors (2)

Lead Sponsor	Collaborator
Sun Yat-sen University	Jiangsu Hengrui Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose-limiting toxicity	Dose limiting toxicities will determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of combination therapy with camrelizumab + apatinib and gemcitabine plus cisplatin. Assessed using the NCI CTCAE v5.0	up to day 22
Primary	Recommended phase 2 dose(RP2D) of apatinib	To determine a RP2D of apatinib for each population of biliary tract carcinoma subjects.	12 weeks
Primary	Objective Response Rate (ORR)	Defined as percentage of participants achieving assessed complete response (CR) and partial response (PR) by the investigator according to the RECIST 1.1.	up to 24 months
Secondary	Adverse Events (AE)	overall incidence of adverse events (AE); incidence of grade 3 or higher AE; incidence of severe adverse events (SAE); incidence of AEs leading to discontinuation of drug use; incidence of AEs leading to suspension of drug use.	up to 24 months
Secondary	Disease Control Rate (DCR)	DCR was defined as the percentage of participants who have a confirmed complete response(CR) or partial response(PR) or stable disease(SD) per RECIST 1.1 as assessed by investigator	up to 24 months
Secondary	Progression-Free Survival (PFS)	PFS is defined as the time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator	up to 24 months
Secondary	Overall Survival (OS)	OS is the time from enrollment to death due to any cause.	up to 24 months